Hangzhou, China, Nov. 04, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, today is pleased to announce that its subsidiary, Neologics Bioscience Inc. (“Neologics”), has entered into a key service agreement (the “Agreement”) with GemPharmatech Corporation (“GemPharmatech”), a Delaware-based leading cont ...

Core Insights - WORK Medical Technology Group LTD has entered into a significant service agreement with GemPharmatech Corporation, marking a pivotal shift in its strategy towards research and development execution [1][5] - Neologics Bioscience Inc., a subsidiary of WORK Medical, will provide various testing services to GemPharmatech for a total payment of US$114,000 [2] - The partnership is expected to accelerate Neologics' business development and reinforce WORK Medical's strategic diversification [5] Company Overview - WORK Medical is a supplier of medical devices in China, developing and manufacturing Class I and II medical devices, with a diverse product portfolio of 21 products sold in 34 provincial-level regions in China and over 30 countries globally [6] - The company has received multiple quality-related manufacturing designations and has registered 17 products with the U.S. FDA, allowing entry into the U.S. market [6] Neologics Bioscience Inc. - Neologics specializes in R&D services, focusing on collaborations with universities, hospitals, and biotechnology firms, and operates a laboratory and R&D center in San Diego, California [3] - The company aims to develop systematic solutions for drug screening and preclinical validation through an independent R&D platform [3] GemPharmatech Corporation - GemPharmatech is a leading contract research organization providing genetically engineered mouse models and preclinical research services, utilizing advanced gene-editing technologies [4] - The company offers a comprehensive suite of services, including mouse model customization and drug efficacy evaluation [4]

Core Insights - Several companies have experienced significant stock price declines due to various underlying factors affecting their performance [1] Company Summaries - **American Rebel Holdings, Inc. (AREB)**: The stock price dropped to $2.50, a decrease of approximately 33.55%. This decline may be linked to market reactions regarding its financial health or operational updates. However, its subsidiary, Champion Safe Company, reported a remarkable 112% year-to-date growth from 2024 to 2025 for Cross Creek Outdoor Supplies [2][8] - **MultiSensor AI Holdings, Inc. (MSAIW)**: The stock price decreased by 33.62%, settling at $0.06. The company's focus on industrial applications has not protected it from volatility in the technology sector, contributing to its recent price movement [3][8] - **Picard Medical, Inc. (PMI)**: The stock price fell by 69.35% to $4.04. This drastic change may be associated with shifts in investor confidence or recent developments within the company, including a new U.S. patent for its fully implantable artificial heart technology [4][8] - **Wheeler Real Estate Investment Trust, Inc. (WHLRL)**: The stock price saw a significant reduction of 35.71%, bringing it down to $90.01. Challenges in the real estate sector, possibly influenced by economic conditions or company-specific news, may have contributed to this decline [5] - **WORK Medical Technology Group Ltd. (WOK)**: The stock price decreased by 32.82% to $2.88. The company's exposure to international markets and dynamics in the healthcare sector could be influencing factors. WORK Medical announced a strategic investment in Neologics Bioscience Inc., acquiring a 10% stake, indicating its interest in integrating artificial intelligence with medicine [6]

Core Points - Work Medical Technology Group Ltd. experienced a significant stock surge of 50.26% in after-hours trading following a 9.19% gain during the regular session, closing at $3.92 [1][2][6] - The company announced a $1 million investment in Neologics Bioscience Inc., acquiring a 10% equity stake, which will increase Neologics' capital reserve to $10 million [2][3] - The investment agreement grants Work Medical corporate governance privileges, including board member nominations and first refusal rights on future equity sales [3][4] Stock Split and Compliance - A 1-for-100 reverse stock split was executed on October 16, reducing the number of outstanding Class A ordinary shares from approximately 96 million to 960,000 to comply with Nasdaq's minimum bid price requirements [4][5] - The reverse stock split was approved by shareholders and the board, aimed at regaining compliance with Nasdaq Marketplace Rule 5550(a)(2) [5] Stock Performance Overview - Work Medical's stock is trading near its 52-week low of $3.50, reflecting a substantial 99.35% loss over the past year, with a market capitalization of $364.46 million and an average daily trading volume of 344,000 shares [6]

Group 1: Minerva Neurosciences, Inc. (NERV) - Minerva Neurosciences, Inc. (NERV) experienced a significant price increase of 224.06%, reaching $8.62 [1] - The company focuses on central nervous system diseases, particularly its lead product candidate, roluperidone, aimed at treating schizophrenia [1] - The FDA has mandated a confirmatory study for roluperidone, indicating regulatory scrutiny and potential future developments [1] Group 2: Tradr ETFs (NVDS, TSLQ) - The Tradr 1.5X Short NVDA Daily ETF (NVDS) saw a price increase of 202.51%, reaching $34.33 [2] - The Tradr 2X Short TSLA Daily ETF (TSLQ) recorded a 201.45% rise, with its price reaching $22.94 [2] - Tradr ETFs has expanded its offerings by launching new 2X long single-stock leveraged ETFs, increasing its lineup to 23 leveraged ETFs [2] Group 3: Market Overview - The substantial gains in NERV and Tradr ETFs highlight the diversity in sectors experiencing significant market movements, including healthcare and financial services [3] - Each sector presents unique investment opportunities and risks, necessitating thorough research by investors [3]

Core Insights - WORK Medical Technology Group LTD executed a reverse stock split at a ratio of 100 for 1 on October 21, 2025, to comply with Nasdaq Marketplace Rule 5550(a)(2) [1] - The reverse stock split was endorsed by the company's shareholders and board of directors, consolidating every 100 shares into one share while maintaining the same trading symbol on the Nasdaq [1] - Following the split, the stock price increased to $4.02, a rise of 12.05% or $0.43, with fluctuations between $3.50 and $4.10 on the reporting day [2] - The company's market capitalization is approximately $229.3 million, with a trading volume of 197,832 shares, indicating a strategic initiative to stabilize stock price and secure Nasdaq listing [2]

Core Insights - WORK Medical Technology Group LTD has entered into an investment agreement to acquire a 10% equity interest in Neologics Bioscience Inc. for US$1 million, enhancing its strategic focus on innovation and collaboration in medical technology [1][3] Investment Details - The investment will increase Neologics's total capital reserve to US$10 million, with existing shareholders retaining a 90% ownership interest [1] - WORK Medical will have corporate governance rights corresponding to its 10% equity interest, including rights to nominate board members and a right of first refusal for future equity interests [1] Use of Proceeds - The investment proceeds are intended to support Neologics's operations, research and development, market expansion, talent acquisition, and other legitimate business purposes [2] Company Overview - WORK Medical is a supplier of medical devices in China, developing and manufacturing Class I and II medical devices, with a diverse product portfolio of 21 products sold in 34 provincial-level regions in China and over 30 countries worldwide [4] - The company has received multiple quality-related manufacturing designations and has registered 17 products with the U.S. Food and Drug Administration, allowing entry into the U.S. market [4]

Core Points - WORK Medical Technology Group LTD will implement a reverse stock split of its ordinary shares on a 1-for-100 basis, effective October 21, 2025 [1][2] - The reverse stock split aims to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) regarding the minimum bid price per share [2] - The total number of outstanding Class A ordinary shares will decrease from approximately 96 million to about 960,000, and Class B ordinary shares will reduce from approximately 7.59 million to around 76,000 [4] Company Overview - WORK Medical is a supplier of medical devices in China, developing and manufacturing Class I and II medical devices, including disposable medical devices [5] - The company has a diverse product portfolio of 21 products, including customized masks, and has sold products in 34 provincial-level regions in China and over 30 countries globally [5] - WORK Medical has received various quality-related manufacturing designations and has registered 17 products with the U.S. FDA for entry into the U.S. market [5]

Core Points - WORK Medical Technology Group LTD has received a determination letter from Nasdaq regarding the delisting of its Class A ordinary shares due to a closing bid price of $0.10 or less for ten consecutive trading days [1][2] - The trading of the Company's Class A ordinary shares will be suspended on October 20, 2025, unless an appeal is filed [2] - The Company plans to appeal the delisting determination by October 16, 2025, which will stay the suspension pending the Panel's decision [3] Company Overview - WORK Medical Technology Group LTD is a supplier of medical devices in China, operating through its subsidiary Work (Hangzhou) Medical Treatment Equipment Co., Ltd. [5] - The Company develops and manufactures Class I and II medical devices, with a diverse product portfolio of 21 products, including customized masks and medical consumables [5] - The products are sold in 34 provincial-level regions in China and in over 30 countries worldwide, with 17 products registered with the U.S. Food and Drug Administration [5] Compliance and Future Actions - The Company is considering all available options to regain compliance with Nasdaq Listing Rules, including the possibility of implementing a reverse share split [4]

Core Points - WORK Medical Technology Group LTD has received a notification from Nasdaq granting an additional 180-calendar-day period to regain compliance with the minimum bid price requirement [1][3] - The initial notice from Nasdaq indicated that WORK Medical's stock had failed to meet the minimum bid price requirement for 30 consecutive business days, leading to an initial compliance period that expired on October 6, 2025 [2] - To regain compliance, WORK Medical's stock must achieve a minimum closing bid price of $1.00 per share for at least 10 consecutive business days during the additional compliance period [4] Company Overview - WORK Medical Technology Group LTD, through its subsidiary, is a supplier of medical devices in China, developing and manufacturing Class I and II medical devices [5] - The company has a diverse product portfolio comprising 21 products, including customized and multifunctional masks, and has sold products in 34 provincial-level administrative regions in China and over 30 countries worldwide [5] - WORK Medical has received quality-related manufacturing designations and has registered 17 products with the U.S. Food and Drug Administration, allowing entry into the U.S. market [5]